Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide
Open Access
- 1 August 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 133 (8), 1263-1275
- https://doi.org/10.1038/sj.bjp.0704199
Abstract
The ability of a series of homologues and analogues of palmitoylethanolamide to inhibit the uptake and fatty acid amidohydrolase (FAAH)‐catalysed hydrolysis of [3H]‐anandamide ([3H]‐AEA) has been investigated. Palmitoylethanolamide and homologues with chain lengths from 12–18 carbon atoms inhibited rat brain [3H]‐AEA metabolism with pI50 values of ∼5. Homologues with chain lengths eight carbon atoms gave R‐palmitoyl‐(2‐methyl)ethanolamide, palmitoylisopropylamide and oleoylethanolamide inhibited [3H]‐AEA metabolism with pI50 values of 5.39 (competitive inhibition), 4.89 (mixed type inhibition) and 5.33 (mixed type inhibition), respectively. With the exception of oleoylethanolamide, the compounds did not produce dramatic inhibition of [3H]‐WIN 55,212‐2 binding to human CB2 receptors expressed on CHO cells. Palmitoylethanolamide, palmitoylisopropylamide and R‐palmitoyl‐(2‐methyl)ethanolamide had modest effects upon [3H]‐CP 55,940 binding to human CB1 receptors expressed on CHO cells. Most of the compounds had little effect upon the uptake of [3H]‐AEA into C6 and/or RBL‐2H3 cells. However, palmitoylcyclohexamide (100 μM) and palmitoylisopropylamide (30 and 100 μM) produced more inhibition of [3H]‐AEA uptake than expected to result from inhibition of [3H]‐AEA metabolism alone. In intact C6 cells, palmitoylisopropylamide and oleoylethanolamide inhibited formation of [3H]‐ethanolamine from [3H]‐AEA to a similar extent as AM404, whereas palmitoylethanolamide, palmitoylcyclohexamide and R‐palmitoyl‐(2‐methyl)ethanolamide were less effective. These data provide useful information upon the ability of palmitoylethanolamide analogues to act as ‘entourage’ compounds. Palmitoylisopropylamide may prove useful as a template for design of compounds that reduce the cellular accumulation and metabolism of AEA without affecting either CB1 or CB2 receptors. British Journal of Pharmacology (2001) 133, 1263–1275; doi:10.1038/sj.bjp.0704199This publication has 56 references indexed in Scilit:
- Characterization of palmitoylethanolamide transport in mouse Neuro‐2a neuroblastoma and rat RBL‐2H3 basophilic leukaemia cells: comparison with anandamideBritish Journal of Pharmacology, 2001
- Endocannabinoids control spasticity in a multiple sclerosis modelThe FASEB Journal, 2000
- Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolaseBritish Journal of Pharmacology, 2000
- Unsaturated Long-Chain N-Acyl-vanillyl-amides (N-AVAMs): Vanilloid Receptor Ligands That Inhibit Anandamide-Facilitated Transport and Bind to CB1 Cannabinoid ReceptorsBiochemical and Biophysical Research Communications, 1999
- Arachidonoylserotonin and Other Novel Inhibitors of Fatty Acid Amide HydrolaseBiochemical and Biophysical Research Communications, 1998
- Fatty Acid Sulfonyl Fluorides Inhibit Anandamide Metabolism and Bind to the Cannabinoid ReceptorBiochemical and Biophysical Research Communications, 1997
- Inhibition of Oleamide Hydrolase Catalyzed Hydrolysis of the Endogenous Sleep-Inducing Lipid cis-9-OctadecenamideJournal of the American Chemical Society, 1996
- Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma ‘anandamide amidohydrolase’FEBS Letters, 1995
- Arachidonoyl ethanolamide-[1,2-14C] as a substrate for anandamide amidaseLife Sciences, 1995
- A proposed autacoid mechanism controlling mastocyte behaviourInflammation Research, 1993